(CLLS)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Name | Position |
|---|---|
| Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director |
| Dr. David J. Sourdive Ph.D. | Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Mr. Arthur Stril | CFO & Chief Business Officer |
| Mr. Jean Charles Epinat Ph.D. | Chief Technological Officer |
| Mr. Stephan Reynier M.Sc. | Chief Regulatory & Pharmaceutical Compliance Officer |
| Ms. Kyung Nam-Wortman | Executive VP & Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-20 | 20-F | clls-20251231.htm |
| 2026-03-12 | 6-K | f6k_031126.htm |
| 2026-01-08 | 6-K | f6k_010826.htm |
| 2025-12-15 | 6-K | f6k_121525.htm |
| 2025-12-08 | 6-K | f6k_120725.htm |
| 2025-12-05 | 6-K | d64018d6k.htm |
| 2025-11-19 | 6-K | f6k_111925.htm |
| 2025-11-07 | 6-K | clls_6-k_q3_2025.htm |
| 2025-11-03 | 6-K | f6k_110325.htm |
| 2025-10-31 | 6-K | f6k_103025.htm |
| Ms. Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer |